Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Fujian Shengdi Pharmaceutical Co., Ltd.
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07559136CT.gov A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity | — | Not Yet Recruiting | — | — | — |
NCT07285902CT.gov A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity | — | Active Not Recruiting | — | — | — |
NCT07150962CT.gov Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects | — | Recruiting | — | — | — |
NCT06841445CT.gov Efficacy and Safety of HRS9531 Tablet in Obese Subjects | — | Completed | — | — | — |
NCT06792955CT.gov The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution | — | Completed | — | — | — |
NCT06762600CT.gov A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects | — | Completed | — | — | — |
NCT06565871CT.gov A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep Apnea | — | Not Yet Recruiting | — | — | — |
NCT06396429CT.gov To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese | — | Completed | — | — | — |
NCT06287437CT.gov HRS9531 Controls Weight Regain in Obese Subjects | — | Unknown | — | — | — |
NCT06054698CT.gov Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects | — | Completed | — | — | — |
Show 1 more trialShow fewer
NCT05881837CT.gov Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| hrs9531 (this asset) | Fujian Shengdi Pharmaceutical Co., Ltd. | P3 | BB · 68 |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| asc30 | Ascletis Pharma (China) Co., Limited | P2 | BBB |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Deoxycholic Acid | University of California, San Diego | P4 | BBB |
| Efsubaglutide Alfa | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
+42 more in the Obesity Disorder cohort
Other indications for hrs9531
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Dysfunction-Associated Steatohepatitis | — | P2 | CCC · 53 |
| Diastolic Heart Failure | — | P2 | CCC · 53 |
| Obstructive Sleep Apnea Syndrome | — | P3 | NR |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. hrs9531 in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/hrs9531-obesity-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →